Pharmaceutical leaders are skeptical of claims that AI could cure most diseases within a decade; the US FDA has yet to clear any AI-designed biotech drugs

AI drug discovery has not yet resulted in any FDA-cleared products, so AI's promised impact on your health is delayed.

Pharmaceutical leaders are skeptical that AI can cure most diseases within a decade, as the US FDA has not yet cleared any AI-designed biotech drugs, with biology being the identified obstacle.

Based on limited preview — the full article may require a subscription

Despite the hype, AI's role in drug development faces significant skepticism from pharmaceutical leaders due to biological complexities. The lack of any FDA-cleared AI-designed drugs highlights the current limitations, suggesting a longer road ahead for this technology to revolutionize healthcare.